---
title: "Dasatinib - Blastic Phase Chronic Myeloid Leukemia"
sidebar: mydoc_sidebar
permalink: db01254-mesh-d001752-1.html
toc: false 
---


Path ID: `DB01254_MESH_D001752_1`
{% include image.html url="images/db01254-mesh-d001752-1.png" file="db01254-mesh-d001752-1.png" alt="db01254-mesh-d001752-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D000069439 | Dasatinib | Drug |
| UniProt:P00519 | Tyrosine-protein kinase ABL1 | Protein |
| GO:0004714 | Transmembrane receptor protein tyrosine kinase activity | MolecularActivity |
| HP:0031377 | Abnormal cell proliferation | PhenotypicFeature |
| MESH:D001752 | Blastic phase chronic myeloid leukemia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Dasatinib | DECREASES ACTIVITY OF | Tyrosine-Protein Kinase Abl1 |
| Tyrosine-Protein Kinase Abl1 | POSITIVELY REGULATES | Transmembrane Receptor Protein Tyrosine Kinase Activity |
| Transmembrane Receptor Protein Tyrosine Kinase Activity | POSITIVELY REGULATES | Abnormal Cell Proliferation |
| Abnormal Cell Proliferation | POSITIVELY CORRELATED WITH | Blastic Phase Chronic Myeloid Leukemia |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB01254](https://go.drugbank.com/drugs/DB01254)
  - [https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia](https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia)
